Transdermal patch
    1.
    发明申请
    Transdermal patch 审中-公开
    透皮贴片

    公开(公告)号:US20090258063A1

    公开(公告)日:2009-10-15

    申请号:US12310840

    申请日:2007-09-11

    IPC分类号: A61K9/70 A61P9/12

    摘要: The present invention provides a transdermal patch having excellent preservation stability and transdermal absorbency of DMAEs. The patch has a support and a plaster layer integrally laminated on one surface of the support, and the plaster layer includes: DMAEs; an acrylic adhesive prepared by copolymerizing monomers respectively containing 30 to 99% by weight of alkyl methacrylate having an alkyl group with a carbon number of 6 to 22 and 1 to 70% by weight of alkyl acrylate having an alkyl group with a carbon number of 2 to 20; and fatty acid ester prepared by dehydro-condensing saturated fatty acid having an alkyl group with a carbon number of 10 to 20 and saturated aliphatic monohydric alcohol having an alkyl group with a carbon number of 2 to 20, wherein solubility of the DMAEs is 0.05 to 5 g at 25° C. with respect to the fatty acid ester.

    摘要翻译: 本发明提供了具有优异的DMAE保存稳定性和透皮吸收性的透皮贴片。 补片具有一体地层叠在支撑体的一个表面上的支撑体和石膏层,并且膏药层包括:DMAE; 通过共聚含有30〜99重量%的具有碳数为6〜22的烷基的甲基丙烯酸烷基酯和1〜70重量%的具有碳原子数为2的烷基的丙烯酸烷基酯的丙烯酸粘合剂 到20 和通过使具有碳原子数为10〜20的烷基的饱和脂肪酸和碳数为2〜20的烷基的饱和脂肪族一元醇脱水缩合而制备的脂肪酸酯,其中DMAE的溶解度为0.05〜 在25℃下相对于脂肪酸酯为5g。

    TRANSDERMAL PATCH
    2.
    发明申请
    TRANSDERMAL PATCH 审中-公开
    透明贴

    公开(公告)号:US20120171274A1

    公开(公告)日:2012-07-05

    申请号:US13351724

    申请日:2012-01-17

    IPC分类号: A61K9/70 A61P9/00 A61K31/137

    摘要: The present invention provides a transdermal patch having excellent preservation stability and transdermal absorbency of DMAEs. The patch has a support and a plaster layer integrally laminated on one surface of the support, and the plaster layer includes: DMAEs; an acrylic adhesive prepared by copolymerizing monomers respectively containing 30 to 99% by weight of alkyl methacrylate having an alkyl group with a carbon number of 6 to 22 and 1 to 70% by weight of alkyl acrylate having an alkyl group with a carbon number of 2 to 20; and fatty acid ester prepared by dehydro-condensing saturated fatty acid having an alkyl group with a carbon number of 10 to 20 and saturated aliphatic monohydric alcohol having an alkyl group with a carbon number of 2 to 20, wherein solubility of the DMAEs is 0.05 to 5 g at 25° C. with respect to the fatty acid ester.

    摘要翻译: 本发明提供了具有优异的DMAE保存稳定性和透皮吸收性的透皮贴片。 补片具有一体地层叠在支撑体的一个表面上的支撑体和石膏层,并且膏药层包括:DMAE; 通过共聚含有30〜99重量%的具有碳数为6〜22的烷基的甲基丙烯酸烷基酯和1〜70重量%的具有碳数为2的烷基的丙烯酸烷基酯的丙烯酸粘合剂 到20 和通过使具有碳原子数为10〜20的烷基的饱和脂肪酸和碳数为2〜20的烷基的饱和脂肪族一元醇脱水缩合而制备的脂肪酸酯,其中DMAE的溶解度为0.05〜 在25℃下相对于脂肪酸酯为5g。

    TRANSDERMAL PATCH
    3.
    发明申请
    TRANSDERMAL PATCH 审中-公开
    透明贴

    公开(公告)号:US20120114738A1

    公开(公告)日:2012-05-10

    申请号:US13351750

    申请日:2012-01-17

    IPC分类号: A61K9/70 A61K31/136

    摘要: The present invention provides a transdermal patch having excellent preservation stability and transdermal absorbency of DMAE or its pharmacologically acceptable salt. The patch has a support and a plaster layer integrally laminated on one surface of the support, and the plaster layer includes: 2-amino-1-(2′,5′-dimethoxyphenyl)ethanol or its pharmacologically acceptable salt; 40 to 98% by weight of acrylic adhesive prepared by copolymerizing monomers respectively containing 30 to 99% by weight of alkyl methacrylate having an alkyl group with a carbon number of 6 to 22 and 1 to 70% by weight of alkyl acrylate having an alkyl group with a carbon number of 2 to 20; and 1 to 30% by weight of saturated aliphatic monohydric alcohol having an alkyl group with a carbon number of 10 to 30.

    摘要翻译: 本发明提供了具有优异的DMAE或其药理学上可接受的盐的保存稳定性和透皮吸收性的透皮贴剂。 贴剂在支撑体的一个表面上具有一体层压的支撑体和石膏层,石膏层包括:2-氨基-1-(2',5'-二甲氧基苯基)乙醇或其药理学上可接受的盐; 通过共聚含有30〜99重量%的具有碳数为6〜22的烷基的甲基丙烯酸烷基酯和1〜70重量%的具有烷基的丙烯酸烷基酯的单体共聚而成的丙烯酸粘合剂为40〜98重量% 碳数为2〜20; 和1〜30重量%的具有碳原子数为10〜30的烷基的饱和脂肪族一元醇。

    Transdermal patch
    4.
    发明申请
    Transdermal patch 审中-公开
    透皮贴片

    公开(公告)号:US20090317452A1

    公开(公告)日:2009-12-24

    申请号:US12310845

    申请日:2007-09-11

    IPC分类号: A61K9/70 A61K31/136 A61P9/02

    摘要: The present invention provides a transdermal patch having excellent preservation stability and transdermal absorbency of DMAE or its pharmacologically acceptable salt. The patch has a support and a plaster layer integrally laminated on one surface of the support, and the plaster layer includes: 2-amino-1-(2′,5′-dimethoxyphenyl)ethanol or its pharmacologically acceptable salt; 40 to 98% by weight of acrylic adhesive prepared by copolymerizing monomers respectively containing 30 to 99% by weight of alkyl methacrylate having an alkyl group with a carbon number of 6 to 22 and 1 to 70% by weight of alkyl acrylate having an alkyl group with a carbon number of 2 to 20; and 1 to 30% by weight of saturated aliphatic monohydric alcohol having an alkyl group with a carbon number of 10 to 30.

    摘要翻译: 本发明提供了具有优异的DMAE或其药理学上可接受的盐的保存稳定性和透皮吸收性的透皮贴剂。 贴剂在支撑体的一个表面上具有一体层压的支撑体和石膏层,石膏层包括:2-氨基-1-(2',5'-二甲氧基苯基)乙醇或其药理学上可接受的盐; 通过共聚含有30〜99重量%的具有碳数为6〜22的烷基的甲基丙烯酸烷基酯和1〜70重量%的具有烷基的丙烯酸烷基酯的单体共聚而成的丙烯酸粘合剂为40〜98重量% 碳数为2〜20; 和1〜30重量%的具有碳原子数为10〜30的烷基的饱和脂肪族一元醇。

    PATCH
    5.
    发明申请
    PATCH 审中-公开
    补丁

    公开(公告)号:US20130287823A1

    公开(公告)日:2013-10-31

    申请号:US13976647

    申请日:2010-12-28

    IPC分类号: A61K9/70 A61K31/165

    摘要: Disclosed is a patch excellent in storage stability and transdermal absorbability of midodrine and having good adhesion. The patch includes a backing and a medicated layer stacked on one surface of the backing so as to be integrated with the backing. The medicated layer contains 3 to 40% by weight of midodrine and 60 to 97% by weight of an acrylic adhesive including a copolymer formed by copolymerization of monomers including 60 to 98% by weight of an alkyl acrylate having an alkyl group with 1 to 12 carbon atoms and 2 to 40% by weight of 1-vinyl-2-pyrrolidone. In the medicated layer, part of midodrine is present in an undissolved state.

    摘要翻译: 本发明公开了一种在米多君的储存稳定性和透皮吸收性优异且贴合性好的贴剂。 补片包括背衬和层叠在背衬的一个表面上的药剂层以便与背衬一体化。 含药层含有3至40重量%的米多君和60至97重量%的丙烯酸粘合剂,包括通过共聚形成的共聚物,所述共聚物包含60至98重量%的具有烷基的丙烯酸烷基酯与1至12个 碳原子和2-40重量%的1-乙烯基-2-吡咯烷酮。 在药物层中,米多君的一部分存在于未溶解状态。